丹参川芎嗪注射液对PCI患者疗效及血清超敏C反应蛋白的影响

目的观察丹参川芎嗪注射液在经皮冠状动脉介入治疗（PCI）患者中的临床疗效和对PCI患者血清超敏C反应蛋白（hsCRP）的影响。方法86例PCI患者随机分为对照组和治疗组，对照组给予常规药物治疗，治疗组在常规药物治疗基础上加用丹参川芎嗪注射液，另选择健康体检者50例作为正常对照组。于治疗前及治疗5d后测定并比较血清（hsCRP）水平，对疗效进行比较。结果治疗组心绞痛缓解有效率（95．45％）明显高于对照组（80．95％）（P〈0．05）；对照组、治疗组治疗前、后血清（hsCRP）水平均明显高于正常对照组（P〈0．01），治疗组治疗后血清（hsCRP）水平明显低于治疗前和对照组（P〈0．01）。结论丹参川芎嗪注射液可明显改善PCI患者的心绞痛症状，也能显著降低血清（hsCRP）水平，并且是安全的。

The effect of danshen lingustrazin for injection on the treatment of PCI patients and the influence on serum high sensitivity C reactive protein

Objective To investigate the effect of danshen ligustrazin for injection on the treatment of pereutaneous coronary intervention （PCI） patients and the influence on serum high-sensitivity C-reactive protein （hsCRP）. Methods Eighty-six patients with PCI were divided randomly into group A and B, and 50 health subjects were selected as group C, patients in group A were treated with conventional medicine, patients in group B were treated with conventional medicine as group A and danshen ligustrazin for injection. All patients were determined serum hs-CRP and evaluated ejection fraction with eehocardiography 5 d before and after treatment respectively, subjects in group C were determined serum hs-CRP, the parameters determined above were studied. Results The remission rate of angina pectoris in group B was significandy higher than that in group A （95.45% vs 80. 95% ,P 〈0.05） ;the serum hs-CRP in group B after treatment was significantly lower than that in group B before treatment and in group C （P 〈0. 05） ;ejection fractions in group B and A after treatment were significandy higher than that before treatment （ P 〈 0. 01 ） , tile difference between group A and B was no significant （ P 〈 0. 01 ）. Conclusion Danshen ligustrazin for injection could effectively alleviate angina pectoris of patients with PCI but also reduce serum levels of hsCRP, and was safe.